NASDAQ:ADAP - Adaptimmune Therapeutics plc
$4.12
 $-0.17
-3.96%
4:00PM EDT
2019-04-18
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ADAP     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 34   203. 85   241. 91  
42 stocks rank:  4. 02 K 1. 44 K 1. 05 K
# analyst opinions:  7. 00   14. 51   13. 97  
mean recommendation:  2. 10   2. 09   2. 01  

quick ratio:  9. 14   5. 27   1. 81  
current ratio:  9. 46   5. 62   2. 25  

target price low:  6. 00   84. 80   115. 21  
target price avg:  4. 14   111. 51   137. 51  
target price high:  5. 41   135. 81   157. 84  
1-yr high:  14. 16   114. 23   138. 78  
last close:  4. 12   87. 66   116. 69  
50-day avg:  4. 40   95. 54   123. 44  
200-day avg:  7. 31   94. 25   121. 11  
1-yr low:  3. 63   72. 78   98. 34  
volume:  302. 06 K 4. 11 M 8. 07 M
50-day avg volume:  271. 41 K 2. 76 M 5. 02 M
200-day avg volume:  450. 36 K 2. 92 M 4. 59 M

1-day return:  -3. 96 % -0. 41 % 0. 07 %
this week return:  -4. 41 % -5. 74 % -4. 11 %
12-wk return:  -12. 15 % 1. 61 % -0. 05 %
52-wk return:  -65. 09 % 3. 12 % 8. 78 %

enterprise value (EV):  226. 19 M 48. 94 B 114. 64 B
market cap:  431. 41 M 43. 07 B 104. 73 B
EBITDA:  -74. 56 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -3. 03   4. 22   12. 73  
enterprise/revenue (EV/R):  3. 80   63. 17   12. 84  
total revenue:  59. 51 M 10. 62 B 38. 47 B
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -95. 51 M 2. 20 B 4. 20 B

shares outstanding:  104. 71 M 571. 70 M 1. 24 B
shares:  43. 24 M 571. 81 M 1. 23 B
shares short:  4. 28 M 10. 17 M 13. 00 M
shares short prior month:  3. 83 M 9. 54 M 17. 33 M
short ratio:  14. 77   5. 41   3. 28  
total cash/share:  1. 96   11. 14   9. 33  
total cash:  205. 13 M 6. 71 B 7. 15 B
free cash flow:  -86. 09 M 3. 58 B 2. 96 B
operating cash flow:  -104. 39 M 4. 15 B 4. 30 B

book value:  2. 36   12. 78   26. 92  
price/book:  1. 75   3. 06   -1. 74  
gross profits:  -38. 76 M 8. 04 B 34. 86 B
operating margins:  -138. 42 % -725. 35 % -89. 04 %
EBITDA margins:  -125. 29 % 10. 94 % 22. 51 %
profit margins:  -160. 51 % 7. 81 % 10. 57 %
gross margins:  -65. 14 % 37. 08 % 55. 70 %

1-yr max volatility:  -29. 83 % --- ---
1-yr mean volatility:  -0. 33 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 98   2. 40   4. 10  
forward EPS:  -1. 15   3. 97   7. 13  
P/E:  -4. 20   13. 63   22. 72  
forward P/E:  -3. 58   -15. 95   13. 99  
PE/G:  0. 06   -1. 65   -1. 32  
growth:  -65. 40 % 127. 12 % 29. 61 %
earnings high:  -0. 26   1. 00   1. 66  
earnings avg:  -0. 31   0. 77   1. 53  
earnings low:  -0. 35   0. 50   1. 39  
revenue high:  4. 00 M 2. 68 B 10. 78 B
revenue avg:  2. 00 M 2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -18. 45 % -2. 75 % 4. 55 %
return on equity:  -42. 46 % -18. 45 % 5. 46 %
revenue growth:  -65. 40 % 92. 86 % 18. 96 %
revenue/share:  0. 61   13. 29   55. 46  

beta (1yr vs S&P500):  1. 15   1. 25   0. 93  
sharpe (1yr):  -1. 10   0. 37   0. 70  

held % insiders:  0. 22 % 6. 39 % 3. 38 %
held % institutions:  73. 00 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : ADAP
.    + 1.049 =         1.049 :: INITIAL WEIGHT
.    + 34.06 =        35.109 :: spline projection addition
.    x 1.431 =        50.256 :: industry recommendation factor
.    x 2.055 =       103.296 :: symbol recommendation factor
.     x 1.06 =       109.511 :: EV/R factor
.    x 0.998 =       109.309 :: return on assets factor
.    x 0.996 =       108.844 :: return on equity factor
.    x 0.993 =       108.133 :: revenue growth factor
.    x 2.319 =       250.708 :: current ratio factor
.     x 1.06 =       265.668 :: quick ratio factor
.    x 1.033 =       274.514 :: short ratio factor
.    x 2.017 =       553.818 :: price-to-book factor
.    x 2.102 =      1164.382 :: P/E weight
.    x 1.986 =      2313.038 :: PE/G factor
.    x 1.452 =      3357.406 :: beta factor
.    x 0.827 =      2774.973 :: sharpe factor
.    x 1.722 =      4778.021 :: target low factor
.    x 1.022 =      4883.377 :: target mean factor
.    x 1.056 =      5156.766 :: target high factor
.     x 1.31 =      6754.785 :: industry 2-weeks return factor
.    x 0.956 =      6457.457 :: overall "drift" factor
.    x 0.999 =       6449.43 :: largest single-day jump factor
.    x 0.077 =       493.831 :: low price factor
.      x 1.0 =       493.751 :: factor hist industry gain for week 16
.   cubeRoot =         7.904 :: reduced to standardize
.   - 25.354 =         0.338 :: add/subtract for performance
.                      0.338 :: FINAL WEIGHT for NASDAQ:ADAP


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org